8 July 2021 LungLife AI, Inc. ("LungLife" or the "Company") Director/PDMR Notification LungLife (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each (“Common Shares”) undertaken by directors. The transactions were […]

• Read More

July 8, 2021

LungLife AI - First Day of Dealings

8 July 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS […]

• Read More

July 6, 2021

LungLife AI - Pricing Confirmation and Publication of Admission Document

2 July 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS […]

• Read More

October 1, 2020

LungLife AI, with Collaborators from Mount Sinai and MD Anderson, to Present Clinical Data on Liquid Biopsy Test for Early Lung Cancer Detection

Thousand Oaks, CA – October 1, 2020 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that clinical data from a research collaboration in early lung cancer detection will be presented at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting taking place on October 2nd […]

• Read More

December 23, 2019

LungLife AI Receives CLIA certification for its Cancer Diagnostic Laboratory

LungLife AI the developer of an Artificial Intelligence (AI) enabled non-invasive liquid biopsy test for the early detection of lung cancer, announced today that the Company has received certification from the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the US Department of Health and Human Services (HHS) Center for […]

• Read More

« Previous 1 … 4 5 6

News & Updates

Our Purpose:To be a driving force in the early detection of lung cancer.

Investor inquiries

Our Purpose:
To be a driving force in the early detection of lung cancer.